search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
COVID-19 Clinical dropout


David Daily, CEO and co-founder, and Chava Hadany, product manager, at Dali Medical Devices respectively, and Ziv Cahani, vice- president of business development and product at Creative IC3D, discuss overcoming clinical trial recruitment obstacles and dropout rates by utilising Synnect.


P


articipating in a clinical trial is not an easy task for a patient. They frequently tend to forget appointments, and forgo the


treatment when studies cause them imposition and inconvenience. Such behaviour leads to an average dropout rate of 30% from clinical studies, and this high dropout rate results in delaying the studies end point and increasing costs. Currently, 50% of study’s are delayed due to recruitment issues, 85% fail to hit their recruitment target and, for many studies, the end point is delayed. Overall, when it comes to clinical trials, patients are difficult to recruit and retain. The ratio of the injectable drugs and biologic drugs in particular, within the clinical pipeline,


has been growing during the past few years. In 2017, 51% of the tested drugs were injectable, whereas in 2019, this rate grew to 55%, as seen in Figure 1. Similarly, the share of biologic drugs has been growing as well, reaching 40% in 2019 – Figure 2. This data supports the growth trend of clinical trials in injectable drugs.


The need – relocate to the home environment Increasing a patients’ comfort is an effective measure to retain patients in a study. Injectable drugs, by their nature, are less convenient to administer and many patients experience needle phobia and anxiety. Such patients are more likely to drop out from a clinical trial in which an


87 | Outsourcing in Clinical Trials Handbook


Outsourcing in Clinical Trials Handbook | 87


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120